As payers began to deal with increased costs in 2021 due to deferred care during the COVID-19 pandemic, they still continued to grapple with the prospect of the impact of future gene therapies’ cost, according to industry experts. Precision’s Phil Cyr (SVP) and Erin Lopata (VP, Access Experience Team) weigh in on new ways to pay for the potential flood of gene therapies for rare diseases brewing in the pipeline.

(more…)

If a genetic therapy was created to cure sickle cell disease, how might this affect the productivity and earnings of an individual with the disease? How might this change also affect wider economic disparities? PRECISIONheor’s Marlon Graf (Senior Research Economist), Rifat Tuly (Research Scientist), and Jeff Sullivan (Senior Director) recently constructed a model to answer these impactful questions.

Click here to learn more about the model and the team’s findings.